MONTREAL, May 13 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma today
announced that Dr Robert Burr has resigned as member of the Company board of
directors. "I would like to extent the appreciation of the board of director
and the entire Biophage Group to Dr Burr for his outstanding contribution and
wish him the best of luck in his future career." commented Dr. Rosemonde
Mandeville, President and CEO of Biophage Pharma.
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage also operates the
Immunotox Labs division, which provides services in Immunogenicity and
Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and
exclusive MELISA(R) for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten, pollens and more
recently Lyme disease (Boreliosis).
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information: Rosemonde Mandeville, M.B., Ch.B., PhD.,
President and CEO, Biophage Pharma Inc., (514) 496-1488,